Navigation Links
Phase 2a Findings Demonstrate that CSL112, A Novel Apolipoprotein A-I Infusion Therapy, Has a Favorable Safety Profile, is Well Tolerated and Increases Cholesterol Efflux Capacity in Stable Atherothrombotic Patients
Date:11/20/2013

dy of CSL112 support our continued enthusiasm for its development as a novel approach to address this important therapeutic void."

About CSL112
CSL112 is a novel formulation of apolipoprotein A-I (apoA-I), the active component of high-density lipoprotein (HDL). It is purified from human plasma and reconstituted to form HDL particles suitable for intravenous infusion. Studies have shown the infusion of CSL112 rapidly elevates markers of reverse cholesterol efflux, a process by which cholesterol is removed from arteries and transported to the liver for clearance. CSL112 may offer a novel option for rapidly stabilizing atherosclerotic lesions and is being studied for reduction in the risk of early atherothrombotic events in acute coronary syndrome (ACS) patients. 

About CSL
Headquartered in Melbourne, Australia, CSL Limited is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the United States, and employs over 11,000 people in more than 25 countries. Visit www.csl.com.au for more information.

Contact

Sheila A. Burke
Director, Communications & Public Relations
Worldwide Commercial Operations
CSL Behring
C: 484-919-2618
Sheila.Burke@cslbehring.com

Eliot Harrison
MCS Healthcare Public Relations
C: 908-884-5252
eharrison@mcspr.com


'/>"/>
SOURCE CSL Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Topokine Commences Phase 2 Clinical Trial of XAF5 Gel to Reduce Submental Fat
2. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Surprise: Viruses Can Cause Disease during Latent Phase; New Evidence Supports Microcompetition Theory
4. RXi Pharmaceuticals Announces the Start of Their First Phase 2 Study with RXI-109 for Treatment of Hypertrophic Scars in Conjunction with Scar Revision Surgery
5. Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
6. GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)
7. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
8. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
9. KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
10. Polaris Group Announces Positive Results for Phase 2 Study of ADI-PEG 20 in Malignant Pleural Mesothelioma
11. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... , ... August 27, 2015 , ... ... Medicine, recently presented new data on the relationship of genetics and hypertension at ... Congress on Heart Disease in Vancouver, British Columbia, Canada. The event, which boasts ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2
... and Germany has developed a new material which is ... room temperature. Previously this was only at all possible ... technically much easier and cheaper to produce than magnetic ... researchers have now found a way to control magnetism ...
... forces can be exploited to make nanoparticle superclusters that ... nanotech applications but hard to accomplish, University of Michigan ... are at work bringing the building blocks of viruses ... are in many ways similar to viruses. ...
... LLC announced today they have been named to the prestigious ... most entrepreneurial and fastest growing companies in America. The 2011 ... the past three years.  HumanTouch is ranked 203 on this ... tier representatives of the Inc. 500 such as Zappos, Patagonia, ...
Cached Biology Technology:Controlling magnetism with electric fields 2Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... , Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... has filed provisional patent 62/198989 for ELECTRONIC ... highlights a method to advance crypto-currencies such as Bitcoin ... a common, uniform way to manage all payments.  ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... report that performing angioplasty (a treatment that involves temporarily ... clogged artery to help widen it) on veins in ... effective way to treat the venous abnormalities found in ... findings were presented at the Society of Interventional Radiology,s ...
... really wants the short end of the stick, in this ... DNA-protein complexes at the ends of chromosomes, can be thought ... fusing with neighboring chromosomes. It is typical for ... time. Now a new study from Brigham and Women,s Hospital ...
... new plants that took effect on 1 January 2012 included ... that descriptions or diagnoses of new species had to be ... take full advantage of an ongoing revolution in how botanists ... to science: Many studies now routinely include the sequencing of ...
Cached Biology News:Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 2Interventional radiology: Mitigating symptoms, improving quality of life of MS patients 3The long, err, short of it 2
... stain was developed specifically for reduced mutagenicity ... DNA in agarose or acrylamide gels. SYBR Safe ... bromide but SYBR Safe stain's detection sensitivity is ... stain comes as a premixed solution that can ...
... This exceptionally sensitive nucleic acid gel stain ... low background in gels, making it ideal for ... standard UV transilluminators. SYBR Green I nucleic ... capillary electrophoresis, real-time PCR assays and bandshift ...
... Todays advanced protein cross-linking techniques are ... text, Dr. Shan S. Wong. This valuable ... reaction schemes and current application references. More ... of protein cross-linking and conjugate preparation ...
... proteomic service includes protein separation by ... the PDQuest software package from Bio-Rad ... spectrometry. In order to meet customers ... data analysis and format of the ...
Biology Products: